Contribution of rare mutational outcomes to broadly neutralizing antibodies

Acta Biochim Biophys Sin (Shanghai). 2022 May 25;54(6):820-827. doi: 10.3724/abbs.2022065.

Abstract

Antibodies are important immune molecules that are elicited by B cells to protect our bodies during viral infections or vaccinations. In humans, the antibody repertoire is diversified by programmed DNA lesion processes to ensure specific and high affinity binding to various antigens. Broadly neutralizing antibodies (bnAbs) are antibodies that have strong neutralizing activities against different variants of a virus. bnAbs such as anti-HIV bnAbs often have special characteristics including insertions and deletions, long complementarity determining region 3 (CDR3), and high frequencies of mutations, often at improbable sites of the variable regions. These unique features are rare mutational outcomes that are acquired during antibody diversification processes. In this review, we will discuss possible mechanisms that generate these rare antibody mutational outcomes. The understanding of the mechanisms that generate these rare mutational outcomes during antibody diversification will have implications in vaccine design strategies to elicit bnAbs.

Keywords: AID; broadly neutralizing antibodies; indels; long CDR H3; somatic hypermutation.

Publication types

  • Review

MeSH terms

  • Antibodies
  • Broadly Neutralizing Antibodies
  • Complementarity Determining Regions*
  • Humans
  • Mutation
  • Vaccines*

Substances

  • Antibodies
  • Broadly Neutralizing Antibodies
  • Complementarity Determining Regions
  • Vaccines

Grants and funding

This work was supported by the grants from the National Key R&D Program of China (Nos. 2020YFA0112900 and 2021YFA1301400), the National Natural Science Foundation of China (Nos. 31722020, 81671634, and 81861138014), and the China Postdoctoral Science Foundation (Nos. 2016M601613 and BX201600107 to Q.H.).